The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Open accessAbstract
BACKGROUND: In patients with severe hemophilia B, gene therapy that is mediated by a novel self-complementary adeno-associated virus serotype 8 (AAV8) vector has been shown to raise factor IX levels for periods of up to 16 months. We wanted to determine the durability of transgene expression, the vector dose-response relationship, and the level of persistent or late toxicity. METHODS: We evaluated the stability of transgene expression and long-term safety in 10 patients with severe hemophilia B: 6 patients who had been enrolled in an initial phase 1 dose-escalation trial, with 2 patients each receiving a low, intermediate, or high dose, and 4 additional patients who received the high dose (2×10(12) vector genomes per kilogram of body weight). The patients subsequently underwent extensive clinical and laboratory monitoring. RESULTS: A single intravenous infusion of vector in all 10 patients with severe hemophilia B resulted in a dose-dependent increase in circulating factor IX to a level that was 1 to 6% of the normal value over a median period of 3.2 years, with observation ongoing. In the high-dose group, a consistent increase in the factor IX level to a mean (±SD) of 5.1±1.7% was observed in all 6 patients, which resulted in a reduction of more than 90% in both bleeding episodes and the use of prophylactic factor IX concentrate. A transient increase in the mean alanine aminotransferase level to 86 IU per liter (range, 36 to 202) occurred between week 7 and week 10 in 4 of the 6 patients in the high-dose group but resolved over a median of 5 days (range, 2 to 35) after prednisolone treatment. CONCLUSIONS: In 10 patients with severe hemophilia B, the infusion of a single dose of AAV8 vector resulted in long-term therapeutic factor IX expression associated with clinical improvement. With a follow-up period of up to 3 years, no late toxic effects from the therapy were reported. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00979238.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further studies confirmed that the capsid-specific immune response is dose-dependent and administration of low vector doses of AAV are more likely to induce mild inflammation that is manageable by steroids [86–88].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [87]
In the citing paper
“The initial clinical studies of AAV-based gene transfer targeting liver correlated the AAV-specific cytotoxic T lymphocytes activation with transaminitis and loss of transgene expression”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [39]
In the citing paper
“therefore studies of AAV immunogenicity focused mainly on the adaptive immune responses against AAV-transduced hepatocytes (38, 39).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [39]
In the citing paper
“Moreover, a recent meta-analysis of clinical trials using hepatic AAV gene transfer concluded that vectors rich in CpG motifs results in failure to achieve sustained expression, owing to activation of capsid specific CD8+ T cells (19–22).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [19]
In the citing paper
“Antibody formation against capsid was also not impacted by CpG depletion in clinical trials (19, 57).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [19]
In the citing paper
“These studies however build evidence that short-course CCS alone is likely to be insufficient to inhibit formation of capsid-reactive T cells (13) and rAAV-mediated immune response with systemic high dosages.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [13]
In the citing paper
“In the subsequent study using AAV8, administration of steroids was able to negate this response and maintain therapeutic FIX levels albeit a 50-70% decline from peak levels (13).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citationSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L. A., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Self-citationNathwani, A. C., Gray, J. T., Ng, C. Y., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball‐Cook, G., McIntosh, J., Boon‐Spijker, M., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 419
Self-citationNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationNathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2006) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 269
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,001
Smith-Moore, S., Neil, S. J. D., Fraefel, C., Linden, R. M., Bollen, M., Rowe, H. M., & Henckaerts, E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721883115 · Cited by 27
Ginocchio, V. M., Ferla, R., Auricchio, A., & Brunetti‐Pierri, N. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.151 · Cited by 29
Cabrera-Pérez, R., Vila‐Julià, F., Hirano, M., Mingozzi, F., Torres‐Torronteras, J., & Martí, R. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.217 · Cited by 28
Self-citationLi, J., Wen, A. M., Potla, R., Benshirim, E., Seebarran, A., Benz, M. A., Henry, O., Matthews, B. D., Prantil‐Baun, R., Gilpin, S. E., et al. (2019) · APL Bioengineering · doi:10.1063/1.5122967 · Cited by 28
Yin, L., Keeler, G. D., Zhang, Y., Hoffman, B. E., Ling, C., Qing, K., & Srivastava, A. (2020) · Gene Therapy · doi:10.1038/s41434-020-0140-1 · Cited by 29
SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
Cnossen, M. H., van Moort, I., Reitsma, S. H., de Maat, M. P. M., Schutgens, R. E. G., Urbanus, R. T., Lingsma, H. F., Mathôt, R. A. A., Gouw, S. C., Meijer, K., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15778 · Cited by 27
Nathwani, A. C., McIntosh, J., & Sheridan, R. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.169 · Cited by 28
Self-citationGene Therapy Approaches for the Treatment of Hemophilia B
Soroka, A. B., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310766 · Cited by 29
Advances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome
Bortolussi, G., & Muro, A. F. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1495558 · Cited by 27
Engineering humoral immunity as prophylaxis or therapy
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.06.014 · Cited by 27
Long, B. R., Robinson, T. M., Day, J. R., Yu, H., Lau, K., Imtiaz, U., Patton, K. S., de Hart, G., Henshaw, J., Agarwal, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.033 · Cited by 29
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 30
Innovative Treatments for Lysosomal Diseases
Cox, T. M. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.01.001 · Cited by 28
Boehme, P., Zhang, W., Solanki, M., Ehrke‐Schulz, E., & Ehrhardt, A. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.44 · Cited by 27
Michler, T., Große, S., Mockenhaupt, S., Röder, N., Stückler, F., Knapp, B. L., Ko, C., Heikenwälder, M. F., Protzer, U., & Grimm, D. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506172 · Cited by 27
Chai, Z., Sun, J., Rigsbee, K. M., Wang, M., Samulski, R. J., & Li, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.005 · Cited by 28
Lee, Y., Conlon, T., Specht, A., Coleman, K., Brown, L. M., Estrella, A., Dambska, M., Dahlberg, K. R., & Weinstein, D. A. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0199-7 · Cited by 26
Barbon, E., Aymé, G., Mohamadi, A., Ottavi, J., Kawecki, C., Casari, C., Verhenne, S., Marmier, S., van Wittenberghe, L., Charles, S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911298 · Cited by 28
Self-citationA primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 28
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 29
Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders
Chen, Y., Wen, R., Yang, Z., & Chen, Z. (2021) · Gene Therapy · doi:10.1038/s41434-021-00247-9 · Cited by 29
Liver-Directed Adeno-Associated Virus–Mediated Gene Therapy for Mucopolysaccharidosis Type VI
Brunetti‐Pierri, N., Ferla, R., Ginocchio, V. M., Rossi, A., Fecarotta, S., Romanò, R., Parenti, G., Yıldız, Y., Zancan, S., Pecorella, V., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200052 · Cited by 28
Self-citationNienhuis, A. W., Nathwani, A. C., & Davidoff, A. M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.018 · Cited by 27
Self-citationMcMullen, J. R., & Drew, B. G. (2016) · Clinical Science · doi:10.1042/cs20160244 · Cited by 29
Discovery and progress of direct cardiac reprogramming
Kojima, H., & Ieda, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2466-4 · Cited by 28
Huang, L., Aghajan, M., Quesenberry, T., Low, A., Murray, S., Monia, B. P., & Guo, S. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0779 · Cited by 27
Liver depot gene therapy for Pompe disease
Kishnani, P. S., & Koeberl, D. D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.02 · Cited by 27
Bell, P., Wang, L., Chen, S.-J., Yu, H., Zhu, Y., Nayal, M., He, Z., White, J., Lebel-Hagan, D., & Wilson, J. M. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.039 · Cited by 26
Mechanisms and Delivery of tRNA Therapeutics
Ward, C., Beharry, A., Tennakoon, R., Rozik, P., Wilhelm, S. D. P., Heinemann, I. U., & O’Donoghue, P. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00142 · Cited by 25
Adeno-associated virus therapies: Pioneering solutions for human genetic diseases
Liu, D., Tian, L., Liu, L., Che, X., Li, X., Liu, C., & Wu, G. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.09.003 · Cited by 29
Increasing the Clinical Potential and Applications of Anti-HIV Antibodies
Hua, C. K., & Ackerman, M. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01655 · Cited by 27
Bosma, P. J., Wits, M., & Elferink, R. P. J. O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010273 · Cited by 27
Gene Therapy for Inherited Bleeding Disorders
Arruda, V. R., Weber, J., & Samelson‐Jones, B. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722862 · Cited by 25
Hart, D. P., Branchford, B. R., Hendry, S., Ledniczky, R., Sidonio, R. F., Négrier, C., Kim, M. H., Rice, M., Minshall, M., Arcé, C., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01555-w · Cited by 28
Directed evolution of adeno-associated virus 5 capsid enables specific liver tropism
Wang, Y., Yang, C., Hu, H., Chen, C., Yan, M., Ling, F., Wang, K. C., Wang, X., Deng, Z., Zhou, X., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.017 · Cited by 27
Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
Bajaj, A., & Cuchel, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17065 · Cited by 28
Horton, R. H., Saade, D. N., Markati, T., Harriss, E., Bönnemann, C. G., Muntoni, F., & Servais, L. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329431 · Cited by 27
Kashiwakura, Y., Baatartsogt, N., Yamazaki, S., Nagao, A., Amano, K., Suzuki, N., Matsushita, T., Sawada, A., Higasa, S., Yamasaki, N., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.014 · Cited by 27
Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency
Yılmaz, B. Ş., & Gissen, P. (2023) · Biomedicines · doi:10.3390/biomedicines11082227 · Cited by 26
Viral vector‐based cancer treatment and current clinical applications
Xie, L., Han, Y., Liu, Y., Zhou, Y., Yu, J., von Brunn, A., & Lei, J. (2023) · MedComm – Oncology · doi:10.1002/mog2.55 · Cited by 28
New Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
Genetic Engineering and Manufacturing of Hematopoietic Stem Cells
Wang, X., & Rivière, I. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.003 · Cited by 25
Yao, J. Q., Li, S., Zhang, L., Yang, Y., Gopinath, S. C. B., Lakshmipriya, T., & Zhou, Y. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.10.156 · Cited by 25
Aronson, S. J., Bakker, R. S., Moenis, S., van Dijk, R., Bortolussi, G., Collaud, F., Shi, X., Duijst, S., ten Bloemendaal, L., Ronzitti, G., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.002 · Cited by 25
Self-citationHemophilia gene therapy—New country initiatives
Reiss, U. M., Zhang, L., & Ohmori, T. (2020) · Haemophilia · doi:10.1111/hae.14080 · Cited by 25
Self-citationWang, L., Muthuramu, I., Somanathan, S., Zhang, H., Bell, P. L., He, Z., Yu, H., Zhu, Y., Tretiakova, A. P., & Wilson, J. M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.017 · Cited by 25
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Garrison, L. P., Pezalla, E., Towse, A., Yang, H., Faust, E., Wu, E. Q., Li, N., Sawyer, E. K., & Recht, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.05.008 · Cited by 25
Self-citationDevelopment of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases
Lin, C., Greenblatt, M. B., Gao, G., & Shim, J. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.022 · Cited by 25
Longer‐acting clotting factor concentrates for hemophilia
Powell, J. S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12912 · Cited by 25
Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII
Marcos-Contreras, O. A., Smith, S. M., Bellinger, D. A., Raymer, R. A., Merricks, E. P., Faella, A., Pavani, G., Zhou, S., Nichols, T. C., High, K. A., et al. (2015) · Blood · doi:10.1182/blood-2015-09-671420 · Cited by 25
Self-citationLytle, A. M., Brown, H. C., Paik, N. Y., Knight, K. A., Wright, J. F., Spencer, H. T., & Doering, C. B. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.56 · Cited by 26
Grisch‐Chan, H. M., Schlegel, A. A., Scherer, T., Allegri, G., Heidelberger, R., Tsikrika, P., Schmeer, M., Schleef, M., Harding, C. O., Häberle, J., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.013 · Cited by 25
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 25
Herzog, R. W., Kuteyeva, V., Saboungi, R., Terhorst, C., & Biswas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00274 · Cited by 24
Deshpande, S., Joseph, K., Tong, J., Chen, Y., Pishko, A. M., & Cuker, A. C. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014111 · Cited by 24
von Drygalski, A., Gomez, E., Giermasz, A., Castaman, G., Key, N. S., Lattimore, S., Leebeek, F. W. G., Miesbach, W., Recht, M., Monahan, P. E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015291 · Cited by 24
Self-citationLiu, J., & Shui, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.014 · Cited by 24
Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy
VandenDriessche, T., & Chuah, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.007 · Cited by 24
Lotfinia, M., Abdollahpour‐Alitappeh, M., Hatami, B., Zali, M. R., & Karimipoor, M. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00557-8 · Cited by 24
Poupiot, J., Verdera, H. C., Hardet, R., Colella, P., Collaud, F., Bartolo, L., Davoust, J. M., Sanatine, P., Mingozzi, F., Richard, I., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.012 · Cited by 27
Self-citationSabbata, G. D., Boisgérault, F., Guarnaccia, C., Iaconcig, A., Bortolussi, G., Collaud, F., Ronzitti, G., Sola, M. S., Vidal, P., Rouillon, J., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.005 · Cited by 25
Self-citationWang, J., & Zhang, L. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104829 · Cited by 25
Gene therapy for hemophilia: Current status and laboratory consequences
Batty, P. A., & Lillicrap, D. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13605 · Cited by 24
Wang, Y.-C., Wu, Y., Choi, J. Y., Allington, G., Zhao, S., Khanfar, M., Yang, K., Fu, P.-Y., Wrubel, M., Yu, X., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020175 · Cited by 23
Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
Zhang, Y., Wang, Y., & Liu, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.011 · Cited by 26
Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice
Pontoizeau, C., Sola, M. S., Gaborit, C., Nguyen, V., Rotaru, I., Tual, N., Colella, P., Girard, M., Biferi, M. G., Arnoux, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30880-w · Cited by 26
Self-citationAdeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector
Srivastava, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.29017.asr · Cited by 23
Gene Therapy for Coagulation Disorders
Swystun, L. L., & Lillicrap, D. (2016) · Circulation Research · doi:10.1161/circresaha.115.307015 · Cited by 24
Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase
Cagin, U., Puzzo, F., Gómez, M. J., Moya‐Nilges, M., Sellier, P., Abad, C., van Wittenberghe, L., Danièle, N., Guerchet, N., Gjata, B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.025 · Cited by 25
Self-citationLoza, L. I. M., Cooney, A. L., Dong, Q., Randak, C. O., Rivella, S., Sinn, P. L., & McCray, P. B. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.020 · Cited by 25
Vandamme, C., Xicluna, R., Hesnard, L., Devaux, M., Jaulin, N., Guilbaud, M., Le Duff, J., Couzinié, C., Moullier, P., Saulquin, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03110 · Cited by 23
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 26
Self-citationAAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement
Pei, X., He, T., Hall, N. E., Gerber, D. A., Samulski, R. J., & Li, C. (2018) · Virology · doi:10.1016/j.virol.2018.02.007 · Cited by 23
Ferrarese, M., Testa, M. F., Balestra, D., Bernardi, F., Pinotti, M., & Branchini, A. (2018) · Human Mutation · doi:10.1002/humu.23404 · Cited by 23
Fuentes, C., & Schaffer, D. V. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.003 · Cited by 27
Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
Te, B., Anglin, C. M., Bridges, P. H., & Cottle, R. N. (2017) · PubMed Central · Cited by 24
Hemophilia gene therapy knowledge and perceptions: Results of an international survey
Peyvandi, F., Lillicrap, D., Mahlangu, J. N., McLintock, C., Pasi, J., Pipe, S. W., Scales, W., Srivastava, A., & VandenDriessche, T. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12326 · Cited by 23
So, W. Y., Liu, W. N., Teo, A. K. K., Rutter, G. A., & Han, W. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb1038 · Cited by 23
Monobac System–A Single Baculovirus for the Production of rAAV
Galibert, L., Jacob, A., Savy, A., Dickx, Y., Bonnin, D., Lecomte, C., Rivollet, L., Sanatine, P., Fontaine, M. B., Bec, C. L., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9091799 · Cited by 25
Shimizu‐Albergine, M., Basu, D., Kanter, J. E., Kramer, F., Kothari, V., Barnhart, S., Thornock, C., Mullick, A. E., Clouet-Foraison, N., Vaisar, T., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153285 · Cited by 24
Vrouwe, J. P. M., Meulenberg, J. J. M., Klarenbeek, N. B., Navas-Cañete, A., Reijnierse, M., Ruiterkamp, G., Bevaart, L., Lamers, R. J., Kloppenburg, M., Nelissen, R. G. H. H., et al. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.09.013 · Cited by 25
Lisjak, M., Caneva, A. D., Marais, T., Barbon, E., Biferi, M. G., Porro, F., Barzel, A., Zentilin, L., Kay, M. A., Mingozzi, F., et al. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.785698 · Cited by 24
Self-citationMedici, G., Tassinari, M., Galvani, G., Bastianini, S., Gennaccaro, L., Loi, M., Mottolese, N., Alvente, S., Berteotti, C., Sagona, G., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01295-8 · Cited by 24
Critchley, B. J., Gaspar, H. B., & Benedetti, S. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.015 · Cited by 25
Westhaus, A., Cabanes‐Creus, M., Dilworth, K. L., Zhu, E., Gómez, D. S., Navarro, R. G., Amaya, A. K., Scott, S., Kwiatek, M., McCorkindale, A. L., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.188 · Cited by 24
Esposito, F., Dell’Aquila, F., Rhiel, M., Auricchio, S., Chmielewski, K. O., Andrieux, G., Ferla, R., Horrach, P. S., Padmanabhan, A., Cunto, R. D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101619 · Cited by 23
Adeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity
Mingozzi, F., & Büning, H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00120 · Cited by 29
Self-citationVerhenne, S., Vandeputte, N., Pareyn, I., Izsvák, Z., Rottensteiner, H., Deckmyn, H., Meyer, S. F. D., & Vanhoorelbeke, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308680 · Cited by 23
Kavita, U., Dai, Y., Salvador, L., Miller, W., Adam, L. P., Lévesque, P., Zhang, Y. J., Ji, Q., & Pillutla, R. C. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.131 · Cited by 23
Chai, Z., Zhang, X., Dobbins, A. L., Rigsbee, K. M., Wang, B., Samulski, R. J., & Li, C. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.233 · Cited by 23
Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases
Berns, K. I., & Srivastava, A. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.005 · Cited by 23
Pinto, C., Silva, G. P. D. L., Ribeiro, A. S., Oliveira, M., Garrido, M., Bandeira, V., Nascimento, A., Coroadinha, A. S., Peixoto, C., Barbas, A., et al. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.05.016 · Cited by 23
Hemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 24
Superior human hepatocyte transduction with adeno-associated virus vector serotype 7
Shao, W., Pei, X., Cui, C., Askew, C., Dobbins, A., Chen, X., Abajas, Y. L., Gerber, D. A., Samulski, R. J., Nichols, T. C., et al. (2019) · Gene Therapy · doi:10.1038/s41434-019-0104-5 · Cited by 22
Zakas, P. M., Cunningham, S. C., Doherty, A., van Dijk, E. B., Ibraheim, R., Yu, S., Mekonnen, B. D., Lang, B., English, E. J., Sun, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.021 · Cited by 22
Han, S.-O., Li, S., McCall, A. L., Arnson, B., Everitt, J. I., Zhang, H., Young, S. P., ElMallah, M. K., & Koeberl, D. D. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.020 · Cited by 24
Vila-Julià, F., Cabrera-Pérez, R., Cámara, Y., Molina-Berenguer, M., Lope-Piedrafita, S., Hirano, M., Mingozzi, F., Torres-Torronteras, J., & Martí, R. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.103133 · Cited by 22
Self-citationAAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study
Hu, H., Mosca, R., Gomero, E. M., van de Vlekkert, D., Campos, Y., Fremuth, L. E., Brown, S. A., Weesner, J. A., Annunziata, I., & d’Azzo, A. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.007 · Cited by 22
Let-7 underlies metformin-induced inhibition of hepatic glucose production
Xie, D., Chen, F., Zhang, Y., Shi, B., Song, J., Chaudhari, K., Yang, S., Zhang, G. J., Sun, X., Taylor, H. S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122217119 · Cited by 24
In vivo adenine base editing reverts C282Y and improves iron metabolism in hemochromatosis mice
Rovai, A., Chung, B., Hu, Q., Hook, S., Yuan, Q., Kempf, T., Schmidt, F., Grimm, D., Talbot, S. R., Steinbrück, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32906-9 · Cited by 21
Metadata
- Authors
- Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., Riddell, A., Pie, J., Rangarajan, S., Bevan, D., Recht, M., Shen, Y.-M., Halka, K. G., Basner-Tschakarjan, E., Mingozzi, F., High, K. A., Allay, J., Kay, M. A., Ng, C. Y. C., Zhou, J., Cancio, M., Morton, C. L., Gray, J. T., Srivastava, D., Nienhuis, A. W., & Davidoff, A. M.
- Affiliations
- NHS Blood and Transplant (GB)
- Royal Free London NHS Foundation Trust (GB)
- University College London (GB)
- St Thomas' Hospital (GB)
- Oregon Health & Science University (US)
- The University of Texas Southwestern Medical Center (US)
- Children's Hospital of Philadelphia (US)
- St. Jude Children's Research Hospital (US)
- Stanford Medicine (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1994-2004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4278802
- OpenAlex
- W1969271703
- Cited by
- 1,273
- References
- 17
- Citations by year
- 2026: 44 · 2025: 64 · 2024: 80 · 2023: 99 · 2022: 118 · 2021: 119 · 2020: 133 · 2019: 125 · 2018: 139 · 2017: 144 · 2016: 108 · 2015: 92 · 2014: 2
- FWCI
- 81.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Assisi Foundation of Memphis
- NHS Blood and Transplant
- American Lebanese Syrian Associated Charities
- National Institute for Health and Care Research (RP-PG-0310-1001, NF-SI-0513-10071)
- University College London
- University College London Hospitals NHS Foundation Trust
- Medical Research Council
- National Heart, Lung, and Blood Institute (HL094396, R01HL094396, R01HL073838, R01HL064274)
- National Cancer Institute (P30CA021765)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, AAV8 vector, self-complementary AAV, dose-response relationship, long-term safety, late toxicity, alanine aminotransferase elevation, bleeding events
- MeSH terms
- Dependovirus, Adult, Alanine Transaminase, Hemophilia B, Factor IX, Follow-Up Studies, Genetic Vectors, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Gene Expression, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
